Ticker: CPHI, Company: CHINA PHARMA HOLDINGS, INC., Type: 10-K, Date: 2013-03-14, XBRL Interactive Financials
Original SEC Filing: Click here

---

Webplus: CPHI/20130314/10-K_1/1/000.htm SEC Original: cphi10k123112.htm
FORM 10-K x For the fiscal year ended December 31, 2012 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each

---

---

Webplus: CPHI/20130314/10-K_1/2_EX-10.1/000.htm SEC Original: cphi10kex101123112.htm
December 24, 2012 Dear Ms. Heung Mei Tsui On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc as a director. The compensation is $16,000 per year. I look forward to working with you. Your starting date will be the December 24, 2012, and

---

---

Webplus: CPHI/20130314/10-K_1/3_EX-10.2/000.htm SEC Original: cphi10kex102123112.htm
Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Yingwen Zhang, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent

---

---

Webplus: CPHI/20130314/10-K_1/4_EX-10.3/000.htm SEC Original: cphi10kex103123112.htm
Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Baowen Dong, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent

---

---

Webplus: CPHI/20130314/10-K_1/5_EX-10.4/000.htm SEC Original: cphi10kex104123112.htm
Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an

---

---

Webplus: CPHI/20130314/10-K_1/6_EX-10.9/000.htm SEC Original: cphi10kex109123112.htm
Loans Extension Agreement With respect to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the Company), the principal and accumulated interest totaled USD $1,354,567 and $17,122 respectively as of December 31, 2012. Because the Company temporarily did not have enough balance in its oversea account to repay the loans, Ms. Tsui and the Company unanimously agreed

---

---

Webplus: CPHI/20130314/10-K_1/7_EX-23.1/000.htm SEC Original: cphi10kex231123112.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of China Pharma

---

---

Webplus: CPHI/20130314/10-K_1/8_EX-31.1/000.htm SEC Original: cphi10kex311123112.htm
CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

---

---

Webplus: CPHI/20130314/10-K_1/9_EX-31.2/000.htm SEC Original: cphi10kex312123112.htm
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,

---

---

Webplus: CPHI/20130314/10-K_1/10_EX-32.1/000.htm SEC Original: cphi10kex321123112.htm
18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 President and Chief Executive Officer EX-32.1 10 cphi10kex321123112.htm

---

---

Webplus: CPHI/20130314/10-K_1/11_EX-32.2/000.htm SEC Original: cphi10kex322123112.htm
18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 (principal financial officer and principal accounting officer) EX-32.2 11 cphi10kex322123112.htm

---

Company Information:

Ticker: CPHI, Company: CHINA PHARMA HOLDINGS, INC., Type: 10-K, Date: 2013-03-14, XBRL Interactive FinancialsCIK: 0001106644, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
2ND FLOOR, NO. 17, JINPAN ROAD, HAIKOU
HAINAN PROVINCE 570216